Atorvastatin

Description

Introducing PharmAlliance International Labs’ Atorvastatin Tablets

Company Introduction:

Welcome to PharmAlliance International Labs Private Limited, where we are dedicated to revolutionizing healthcare through innovative pharmaceutical solutions. With a steadfast commitment to quality and patient well-being, we are proud to introduce our Atorvastatin Tablets, a trusted medication for managing lipid disorders and reducing cardiovascular risk.

Drug Classification:

Atorvastatin belongs to the class of medications known as statins, which are potent inhibitors of HMG-CoA reductase. By blocking this enzyme, atorvastatin effectively decreases the synthesis of cholesterol in the liver and lowers circulating levels of LDL cholesterol, thereby reducing the risk of cardiovascular events.

Formulations:

PharmAlliance International Labs offers Atorvastatin Tablets in various strengths, including 10mg, 20mg, and 40mg formulations. These oral tablets are conveniently packaged in blister packs containing 28 tablets each, ensuring precise dosing and ease of administration.

Indications:

Atorvastatin Tablets are indicated for the treatment of hyperlipidemia, characterized by elevated levels of cholesterol and triglycerides. Additionally, they are prescribed for the prevention of cardiovascular events, including myocardial infarction, stroke, and coronary revascularization procedures, in patients with established coronary heart disease or other risk factors.

Usage:

Patients should take Atorvastatin Tablets orally, with or without food, as directed by a healthcare professional. Dosage regimens may vary based on individual lipid profiles, cardiovascular risk factors, and treatment responses. Regular monitoring of lipid levels and liver function tests is recommended to assess treatment efficacy and detect potential adverse effects.

Dosage:

The recommended starting dose of Atorvastatin is typically 10-20 mg once daily, with adjustments made based on lipid levels and treatment responses. For patients requiring more aggressive lipid lowering, a starting dose of 40mg may be considered. Dosage should be individualized and titrated carefully to achieve optimal lipid control while minimizing adverse effects.

Pharmacokinetics:

Atorvastatin is well absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver, where it is converted to its active form. The active metabolites of atorvastatin inhibit HMG-CoA reductase, leading to decreased cholesterol synthesis and increased clearance of LDL cholesterol from the bloodstream.

Pharmacodynamics:

By reducing LDL cholesterol levels and promoting the clearance of atherogenic lipoproteins, atorvastatin helps prevent the progression of atherosclerosis and the occurrence of cardiovascular events. Additionally, atorvastatin exhibits anti-inflammatory and antioxidant properties that may contribute to its cardiovascular protective effects.

Side Effects:

Common side effects associated with atorvastatin therapy may include headache, myalgia (muscle pain), gastrointestinal disturbances (nausea, diarrhea, constipation), and fatigue. Rare but serious adverse effects such as myopathy (muscle damage), rhabdomyolysis (severe muscle breakdown), and hepatotoxicity (liver damage) may occur and require prompt medical attention.

Experience the proven efficacy and cardiovascular benefits of PharmAlliance International Labs’ Atorvastatin Tablets. For more information, please contact us. We are committed to promoting heart health and enhancing patient well-being through our pharmaceutical products.